Muscular Ventricular Septal Defect

No Results

No Results


Trabecular (muscular) ventricular septal defect (VSD) is the second most common type of VSD, occurring in 5-20% of most series. Trabecular muscular VSDs are divided into separate distinct regional groups, including midmuscular, apical, anterior, and posterior. [1] Midmuscular is the most common subtype of muscular VSD. Defects occurring centrally or along the margin of the interventricular septum and free wall are termed anterior VSDs. (See Epidemiology.)

When multiple muscular VSDs occur with a very large communication between the ventricles, it is also known as “Swiss cheese” VSD. Frequently, spontaneous closure of small muscular VSDs occurs in the first 2 years of life (usually by age 6 mo). (See Prognosis.)

Normal closure of the ventricular septum occurs through multiple concurrent embryologic mechanisms that help to close the membranous portion of the septum: (1) downward growth of the conotruncal ridges forming the outlet septum, (2) growth of the endocardial cushions forming the inlet septum, and (3) growth of the muscular septum forming the apical and midmuscular portions of the septum.

VSDs occur when any portion of the ventricular septum does not correctly form or if any of components do not appropriately grow together. The ventricular septum is complete by 6 weeks’ gestation. VSDs are typically classified according to the location of the defect in one of the 4 ventricular components: the inlet septum, trabecular septum, outlet/infundibular septum, or membranous septum. This article specifically addresses defects in the trabecular muscular septum. (See Etiology.)

The precise etiology of muscular septal defect formation is unknown. However, the proposed mechanisms are many. Muscular defects may occur because of a lack of merging in the walls of the trabecular septum or because of excessive resorption of muscular tissue during ventricular growth and remodeling. (See Etiology.)

Complications of VSDs may include the following (see Clinical and Workup):

Congestive heart failure

Bacterial endocarditis

Eisenmenger syndrome

Aortic insufficiency

Subaortic stenosis

Double-chambered right ventricle

Advise the patient and/or his or her parents regarding the risks of bacterial endocarditis and the importance of oral hygiene. Educate them concerning signs and symptoms of CHF.

For patient education information, see the Heart Health Center, as well as Ventricular Septal Defect.

Independent of the type of ventricular septal defect (VSD), the hemodynamic significance of a VSD is determined by 2 factors: the size of the defect and the resistance to flow out of the right ventricle, including the pulmonary vascular resistance (PVR) and anatomic right ventricular outflow obstruction.

In small to moderate VSDs, left-to-right shunting is primarily limited by the size of the defect. Conversely, in large VSDs without right ventricular outflow obstruction, the left-to-right shunting is determined by the relative degree of PVR and systemic vascular resistance.

Because PVR is high at birth and does not reach its nadir until age 6-8 weeks, the development of significant left-to-right shunting and pulmonary overcirculation, often termed congestive heart failure (CHF), can be delayed until the second or third month of life. Additional cardiac lesions that increase left-to-right shunting (eg, atrial septal defect, patent ductus arteriosus) may predispose patients to earlier development of CHF. Noncardiac abnormalities, including prematurity, infection, anemia, or other congenital anomalies, also may predispose infants to significant symptoms of heart failure.

Additional congenital heart lesions (eg, muscular right ventricular outflow tract obstruction, pulmonary valve stenosis, pulmonary venous obstruction, persistent elevation of PVR, mitral stenosis) can restrict shunting, possibly leading to right-to-left trans-VSD flow, depending on the ultimate resistance balance between the systemic and the total right-sided resistances.

Muscular ventricular septal defects (VSDs) have a multifactorial etiology and are predominantly the result of spontaneous abnormalities in development. [2] No correlation with maternal age or birth order is observed.

VSD is the most common congenital heart lesion in most chromosomal anomalies and syndromes. VSD is especially common in patients with trisomy 13, trisomy 18, and trisomy 21. In addition, there are numerous single-gene deletion syndromes associated with VSDs. However, the majority of VSDs (>95%) are not associated with chromosomal abnormalities. [3]

Noncardiac conditions associated with VSD are prematurity, syndromes, and chromosomal anomalies. Regular maternal cannabis slightly increases the incidence of VSD, as does the use of selective serotonin reuptake inhibitors (SSRIs) during early pregnancy. [4, 5]

Ventricular septal defects (VSDs) are slightly more common in females than in males. Large muscular VSDs may not present until age 6-8 weeks, when decreased PVR allows significant left-to-right shunting and the appearance of clinical signs and symptoms of CHF. Most muscular VSDs present clinically in the neonatal period. Typically, these defects, especially the smaller ones, are not suspected at birth and may not be identified by auscultation until the PVR begins to fall in the first few days to weeks of life.

The VSD may manifest soon after birth if it is associated with significant additional congenital heart lesions or if it occurs with an associated chromosomal anomaly or syndrome.

Without regard to type, VSD is the most common congenital heart defect in the first 3 decades of life, with an incidence between 1.5-4.2 cases for every 1000 live term infants. One study described an incidence of muscular VSD of 2.7 cases per 1000 live births. [6]

VSD is more common in premature infants, with an incidence of 4.5-7 cases for every 1000 live births. Clinically significant VSD that requires medical or surgical management accounts for only 15% of such defects (0.35-0.50 cases for every 1000 live births). When viewing congenital heart disease in total, solitary VSD cases account for 20% of congenital heart disease.

Muscular VSD is the second most common type of VSD, accounting for as many as 40% of VSD cases identified in most surgical or autopsy series.

The prevalence of VSD worldwide is relatively constant. However, the type of VSD that predominates in a region widely varies. In the United States, perimembranous VSDs are most common. In Asia, subaortic VSDs (outlet type) are most common. [7]

Children with small to moderate-sized ventricular septal defects (VSDs) have an excellent prognosis. Infants and children with large VSDs have a good, overall prognosis. Optimal medical management with appropriate timing of surgical intervention in these patients has the best outcome. However, patients with multiple muscular VSDs have a more variable prognosis.

Muscular VSDs may spontaneously decrease in size and eventually close. Small muscular VSDs have the greatest likelihood of spontaneous closure, with closure rates approaching 80-90% by age 2 years. Muscular defects in these patients decrease in size due to growth of the ventricular myocardium, which fills in the defect. One study that used fetal echocardiography showed that 33% of all defects closed in utero, 44% of defects spontaneously closed within the first postnatal year, and 23% of defects did not close. [8]

Morbidity and mortality associated with VSDs are influenced by the number and size of the defects, the degree of left-to-right shunting, the presence of associated congenital heart defects, the presence of associated noncardiac defects and syndromes, and the patient’s age at repair of the VSD.

For patients with large muscular VSDs, surgical repair is indicated at any time during the first year of life if the infant fails to grow appropriately despite optimal medical management. Surgical risk and mortality for patients with large VSDs are higher in the first 2 months of life (10-20%) than after age 6 months (1-2%), although these figures are currently decreasing. Elective surgical closure of large VSDs should be planned within the first year of life to prevent development of irreversible pulmonary vascular obstructive disease (ie, Eisenmenger syndrome).

Multiple muscular VSDs, also known as Swiss cheese ventricular septum, are significantly more complex. Patients often show early signs of CHF. This lesion may require staged surgical palliation.

Ramaciotti C, Vetter JM, Bornemeier RA, Chin AJ. Prevalence, relation to spontaneous closure, and association of muscular ventricular septal defects with other cardiac defects. Am J Cardiol. 1995 Jan 1. 75(1):61-5. [Medline].

Newman TB. Etiology of ventricular septal defects: an epidemiologic approach. Pediatrics. 1985 Nov. 76(5):741-9. [Medline].

Nicolae MI, Summers KM, Radford DJ. Familial muscular ventricular septal defects and aneurysms of the muscular interventricular septum. Cardiol Young. 2007 Oct. 17(5):523-7. [Medline].

Williams LJ, Correa A, Rasmussen S. Maternal lifestyle factors and risk for ventricular septal defects. Birth Defects Res A Clin Mol Teratol. 2004 Feb. 70(2):59-64. [Medline].

Oberlander TF, Warburton W, Misri S, Riggs W, Aghajanian J, Hertzman C. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B Dev Reprod Toxicol. 2008 Feb. 83(1):68-76. [Medline].

Reller MD, Strickland MJ, Riehle-Colarusso T, Mahle WT, Correa A. Prevalence of Congenital Heart Defects in Metropolitan Atlanta, 1998-2005. J Pediatr. 2008 Jul 25. [Medline].

Kapoor R, Gupta S. Prevalence of congenital heart disease, Kanpur, India. Indian Pediatr. 2008 Apr. 45(4):309-11. [Medline].

Axt-Fliedner R, Schwarze A, Smrcek J, et al. Isolated ventricular septal defects detected by color Doppler imaging: evolution during fetal and first year of postnatal life. Ultrasound Obstet Gynecol. 2006 Mar. 27(3):266-73. [Medline].

Bahtiyar MO, Dulay AT, Weeks BP, Friedman AH, Copel JA. Prenatal course of isolated muscular ventricular septal defects diagnosed only by color Doppler sonography: single-institution experience. J Ultrasound Med. 2008 May. 27(5):715-20. [Medline].

van den Bosch AE, Ten Harkel DJ, McGhie JS, et al. Feasibility and accuracy of real-time 3-dimensional echocardiographic assessment of ventricular septal defects. J Am Soc Echocardiogr. 2006 Jan. 19(1):7-13. [Medline].

Alsoufi B, Karamlou T, Osaki M, et al. Surgical repair of multiple muscular ventricular septal defects: the role of re-endocardialization strategy. J Thorac Cardiovasc Surg. 2006 Nov. 132(5):1072-80. [Medline].

Kadner A, Dave H, Dodge-Khatami A, et al. Inferior partial sternotomy for surgical closure of isolated ventricular septal defects in children. Heart Surg Forum. 2004. 7(5):E467-70. [Medline].

Amin Z, Cao QL, Hijazi ZM. Closure of muscular ventricular septal defects: Transcatheter and hybrid techniques. Catheter Cardiovasc Interv. 2008 Jul 1. 72(1):102-11. [Medline].

Aleem IS, Karamlou T, Benson LN, McCrindle BW. Transcatheter device versus surgical closure of ventricular septal defects: a clinical decision analysis. Catheter Cardiovasc Interv. 2006 Apr. 67(4):630-6. [Medline].

Crossland DS, Wilkinson JL, Cochrane AD, d’Udekem Y, Brizard CP, Lane GK. Initial results of primary device closure of large muscular ventricular septal defects in early infancy using periventricular access. Catheter Cardiovasc Interv. 2008 Sep 1. 72(3):386-91. [Medline].

Szkutnik M, Kusa J, Bialkowski J. Percutaneous closure of post-traumatic and congenital muscular ventricular septal defects with the Amplatzer Muscular VSD Occluder. Kardiol Pol. 2008 Jul. 66(7):715-20; discussion 721. [Medline].

Vasilyev NV, Melnychenko I, Kitahori K, et al. Beating-heart patch closure of muscular ventricular septal defects under real-time three-dimensional echocardiographic guidance: a preclinical study. J Thorac Cardiovasc Surg. 2008 Mar. 135(3):603-9. [Medline].

Holzer R, Balzer D, Cao QL, Lock K, Hijazi ZM. Device closure of muscular ventricular septal defects using the Amplatzer muscular ventricular septal defect occluder: immediate and mid-term results of a U.S. registry. J Am Coll Cardiol. 2004 Apr 7. 43(7):1257-63. [Medline].

Kang SL, Tometzki A, Caputo M, Morgan G, Parry A, Martin R. Longer-term outcome of perventricular device closure of muscular ventricular septal defects in children. Catheter Cardiovasc Interv. 2015 May. 85 (6):998-1005. [Medline].

Crossland DS, Wilkinson JL, Cochrane AD, d’Udekem Y, Brizard CP, Lane GK. Initial results of primary device closure of large muscular ventricular septal defects in early infancy using periventricular access. Catheter Cardiovasc Interv. 2008 Sep 1. 72(3):386-91. [Medline].

Kim SJ, Huh J, Song JY, Yang JH, Jun TG, Kang IS. The hybrid perventricular closure of apical muscular ventricular septal defect with Amplatzer duct occluder. Korean J Pediatr. 2013 Apr. 56(4):176-81. [Medline]. [Full Text].

Haponiuk I, Chojnicki M, Jaworski R, Steffek M, Juscinski J, Sroka M, et al. Hybrid approach for closure of muscular ventricular septal defects. Med Sci Monit. 2013 Jul 29. 19:618-24. [Medline]. [Full Text].

Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2007 Oct 9. 116(15):1736-54. [Medline].

Michael D Taylor, MD, PhD Director, Advanced Imaging Innovation, Cincinnati Children’s Hospital Medical Center; Assistant Professor, Department of Pediatrics, University of Cincinnati College of Medicine

Michael D Taylor, MD, PhD is a member of the following medical societies: American College of Cardiology, American Heart Association, Society for Cardiovascular Magnetic Resonance

Disclosure: Nothing to disclose.

Benjamin W Eidem, MD, FACC, FASE Professor of Pediatrics and Medicine, Departments of Pediatrics and Medicine, Divisions of Pediatric Cardiology and Cardiovascular Diseases, Mayo Medical School

Benjamin W Eidem, MD, FACC, FASE is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American College of Cardiology, American Heart Association, American Society of Echocardiography, Society for Pediatric Research, Society of Pediatric Echocardiography

Disclosure: Nothing to disclose.

Stuart Berger, MD Executive Director of The Heart Center, Interim Division Chief of Pediatric Cardiology, Lurie Childrens Hospital; Professor, Department of Pediatrics, Northwestern University, The Feinberg School of Medicine

Stuart Berger, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Cardiology, American College of Chest Physicians, American Heart Association, Society for Cardiovascular Angiography and Interventions

Disclosure: Nothing to disclose.

Juan Carlos Alejos, MD Clinical Professor, Department of Pediatrics, Division of Cardiology, University of California, Los Angeles, David Geffen School of Medicine

Juan Carlos Alejos, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Cardiology, American Heart Association, American Medical Association, and International Society for Heart and Lung Transplantation

Disclosure: Actelion Honoraria Speaking and teaching

Hugh D Allen, MD Professor, Department of Pediatrics, Division of Pediatric Cardiology and Department of Internal Medicine, Ohio State University College of Medicine

Hugh D Allen, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Cardiology, American Heart Association, American Pediatric Society, American Society of Echocardiography, Society for Pediatric Research, Society of Pediatric Echocardiography, and Western Society for Pediatric Research

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Muscular Ventricular Septal Defect

Research & References of Muscular Ventricular Septal Defect|A&C Accounting And Tax Services